Acoustic Neuroma

📘

Definitions

1

Vestibular schwannoma definition

Vestibular schwannoma is a benign tumor of neoplastic Schwann cells on the eighth cranial nerve.

CASE_DEFINITION General disease definition for acoustic neuroma / vestibular schwannoma

Show evidence (1 reference)

PMID:38892775 SUPPORT Human Clinical

"Vestibular schwannoma (VS) is a benign tumor of the eighth cranial nerve formed from neoplastic Schwann cells."

This systematic review abstract provides a concise disease-level definition.

◆

Subtypes

2

clinical context

Sporadic Unilateral Acoustic Neuroma

Most acoustic neuromas are unilateral sporadic tumors managed according to size, hearing status, symptoms, growth, and patient factors.

Show evidence (1 reference)

PMID:39627752 SUPPORT Human Clinical

"This study aimed to explore the effect of observation, microsurgery, and radiotherapy for patients with vestibular schwannoma (VS)."

This treatment network meta-analysis is explicitly scoped to unilateral VS, supporting a unilateral management context.

genetic context

NF2-Related Vestibular Schwannoma

Vestibular schwannomas in NF2-related schwannomatosis are typically bilateral and occur as part of a genetic tumor-predisposition syndrome.

Show evidence (1 reference)

PMID:38928264 SUPPORT Human Clinical

"NF2-related schwannomatosis (NF2) is a genetic syndrome characterized by the growth of benign tumors in the nervous system, particularly bilateral vestibular schwannomas, meningiomas, and ependymomas."

The review abstract directly supports bilateral vestibular schwannomas as a key NF2-related disease manifestation.

⚙

Pathophysiology

5

NF2 Merlin Tumor-Suppressor Loss

Loss or dysfunction of NF2/merlin is the central upstream molecular event in NF2-related vestibular schwannoma and a recurrent driver in schwannoma biology. Merlin normally coordinates contact, proliferation, and motility signals; loss of this restraint promotes tumorigenesis.

Schwann cell link

NF2 link

cell cycle checkpoint signaling link ↓ DECREASED

Experimental models

NF2-null schwannoma primary-cell model PRIMARY CELL CULTURE

Downstream

YAP TAZ TEAD-Driven Schwannoma Growth Merlin loss releases downstream Hippo/YAP/TAZ-TEAD proliferative programs.

Show evidence (2 references)

PMID:38928264 SUPPORT Human Clinical

"Merlin, a tumor suppressor, integrates multiple signaling pathways that regulate cell contact, proliferation, and motility, thereby influencing tumor growth."

This supports merlin as a tumor suppressor coordinating processes relevant to schwannoma growth.

PMID:38928264 SUPPORT Human Clinical

"The loss of Merlin disrupts these pathways, leading to tumorigenesis."

This directly supports the causal edge from merlin loss to tumor formation.

YAP TAZ TEAD-Driven Schwannoma Growth

NF2-null schwannoma cells depend on Hippo-pathway effector activity, including YAP/TAZ-driven TEAD transcriptional output, to sustain tumor-cell growth. This mechanism is experimentally targetable in human primary tumor cells and mouse models.

Schwann cell link

NF2 link

positive regulation of Schwann cell proliferation link ↑ INCREASED

Experimental models

NF2-null schwannoma primary-cell model PRIMARY CELL CULTURE

Downstream

VEGF-Mediated Angiogenesis NF2-null schwannoma growth is linked to pro-angiogenic VEGF biology.

mTORC1 Signaling NF2-related schwannoma biology creates a rationale for mTORC1-directed therapy.

Vestibulocochlear Nerve Dysfunction Tumor growth on the eighth cranial nerve disrupts auditory and vestibular function.

Show evidence (2 references)

PMID:36148553 SUPPORT In Vitro

"driven by the TAZ protein in human and mouse NF2-null schwannoma cells"

This supports TAZ-driven signaling in NF2-null schwannoma cells.

PMID:36148553 SUPPORT Model Organism

"successful use of TEAD palmitoylation inhibitors in a preclinical mouse model of schwannoma points to their potential future clinical use."

This supports in vivo mouse-model evidence for TEAD inhibition as a schwannoma growth mechanism.

VEGF-Mediated Angiogenesis

VEGF-related angiogenic signaling contributes to NF2-related vestibular schwannoma treatment biology and provides the mechanistic rationale for bevacizumab.

angiogenesis link ↑ INCREASED

Show evidence (1 reference)

PMID:39685944 SUPPORT Human Clinical

"Bevacizumab, a VEGF-targeting monoclonal antibody, has emerged as a less invasive treatment option, showing potential for tumor volume reduction and hearing preservation."

This supports VEGF as the treatment-linked angiogenic mechanism targeted by bevacizumab in NF2-related VS.

mTORC1 Signaling

mTORC1 signaling is implicated as a downstream actionable pathway in progressive NF2-related vestibular schwannoma, motivating everolimus therapy.

TOR signaling link ↑ INCREASED

Show evidence (1 reference)

PMID:38372904 SUPPORT Human Clinical

"Pre-clinical studies highlighted the potential of mTORC1 inhibition in delaying schwannoma progression."

This supports mTORC1 signaling as the mechanism targeted by everolimus in progressive NF2-related VS.

Vestibulocochlear Nerve Dysfunction

Tumor growth along cranial nerve VIII and in the internal auditory canal/cerebellopontine-angle region impairs auditory and vestibular signaling; larger tumors can affect adjacent cranial nerves and posterior fossa structures.

vestibulocochlear nerve link cerebellopontine angle link

Downstream

Sensorineural Hearing Impairment Cochlear nerve involvement produces hearing impairment.

Tinnitus Eighth-nerve tumor effects can produce persistent tinnitus.

Vestibular Symptoms Vestibular nerve involvement produces vertigo or disequilibrium.

Show evidence (1 reference)

PMID:38892775 SUPPORT Human Clinical

"Although VS can cause a variety of symptoms, tinnitus is one of the most distressing symptoms for patients and can greatly impact quality of life."

This supports symptomatic auditory morbidity from vestibular schwannoma.

⬡

Pathograph

Use the checkboxes to hide or show graph categories. Hover nodes for evidence and cross-linked metadata.

●

Phenotypes

6

Ear 3

Sensorineural Hearing Impairment Hearing impairment (HP:0000365)

Course: PROGRESSIVE

Show evidence (1 reference)

PMID:39045727 SUPPORT Human Clinical

"Hearing loss is a common symptom associated with vestibular schwannoma (VS), either because of the tumor's effects on the cochlear nerve or due to active treatments such as surgery or stereotactic radiosurgery (SRS)."

This directly supports hearing loss as a common acoustic-neuroma manifestation.

Tinnitus Tinnitus (HP:0000360)

Show evidence (1 reference)

PMID:38892775 SUPPORT Human Clinical

"Although VS can cause a variety of symptoms, tinnitus is one of the most distressing symptoms for patients and can greatly impact quality of life."

This directly supports tinnitus as a clinically important VS symptom.

Vestibular Symptoms Vertigo (HP:0002321)

Show evidence (1 reference)

PMID:39627752 SUPPORT Human Clinical

"In terms of improving the rate of disequilibrium/vertigo, the order from the highest to the lowest was SRS, Observation, FSRT 3 fractions, FSRT 5 fractions, MS, and ConFSRT."

This supports disequilibrium/vertigo as a tracked clinical outcome in unilateral VS treatment studies.

Nervous System 1

Headache Headache (HP:0002315)

Show evidence (1 reference)

DOI:10.37897/rjn.2024.3.7 SUPPORT Human Clinical

"Common symptoms included hearing loss (63.6%), disequilibrium (50%), and headaches (39.7%)."

This retrospective cohort directly supports headache as a common acoustic-neuroma symptom.

Other 2

Facial Nerve Dysfunction

Show evidence (1 reference)

PMID:37402894 SUPPORT Human Clinical

"Here, we performed a systematic review and meta-analysis of proton beam for VSs, evaluating tumor control and cranial nerve preservation rates, particularly with regard to facial and hearing preservation."

This supports facial nerve function as a clinically important cranial-nerve outcome in VS.

Trigeminal Nerve Dysfunction

Show evidence (1 reference)

PMID:39627752 SUPPORT Human Clinical

"In terms of protection of the trigeminal nerve, the order from the highest to lowest was observation, SRS, ConFSRT, FSRT 3 fractions, FSRT 5 fractions, and MS."

This supports trigeminal nerve dysfunction risk as an outcome considered in treatment comparisons.

🧬

Genetic Associations

1

NF2 loss or dysfunction (Causal tumor suppressor gene in NF2-related disease and a key schwannoma driver.)

Show evidence (1 reference)

PMID:38928264 SUPPORT Human Clinical

"This review consolidates the current knowledge on NF2 syndrome, emphasizing the molecular pathology associated with the mutations in the gene of the same name, the NF2 gene, and the subsequent dysfunction of its product, the Merlin protein."

This supports NF2 mutation and merlin dysfunction as central molecular pathology.

💊

Treatments

7

Observation

Observation is a standard management option for selected unilateral tumors, especially when symptoms, size, growth, and patient factors favor surveillance over immediate intervention.

Show evidence (1 reference)

PMID:39627752 SUPPORT Human Clinical

"This study aimed to explore the effect of observation, microsurgery, and radiotherapy for patients with vestibular schwannoma (VS)."

This supports observation as one of the treatment strategies compared for unilateral VS.

Microsurgical Resection

Action: surgical procedure MAXO:0000004

Microsurgery offers tumor removal and local control but must be balanced against risks to hearing and adjacent cranial nerves.

Mechanism Target:

INHIBITS YAP TAZ TEAD-Driven Schwannoma Growth — Microsurgical tumor removal directly reduces tumor burden.

Target Phenotypes: Hearing impairment ↗

Show evidence (1 reference)

PMID:39045727 SUPPORT Human Clinical

"Microsurgery demonstrated a higher prevalence of maintaining long-term serviceable hearing, with a pooled estimate of 74.5% (95% CI: 63.5%-84.1%)."

This supports microsurgery as an active VS treatment with reported long-term hearing-preservation outcomes in selected cohorts.

Stereotactic Radiosurgery

Action: stereotactic radiosurgery MAXO:0009088

Stereotactic radiosurgery is an active tumor-control strategy for selected acoustic neuromas and may preserve nerve function better than microsurgery in some treatment comparisons.

Mechanism Target:

INHIBITS YAP TAZ TEAD-Driven Schwannoma Growth — Stereotactic radiosurgery is used to control tumor growth.

Target Phenotypes: Vertigo or disequilibrium ↗

Show evidence (1 reference)

PMID:39627752 SUPPORT Human Clinical

"In patients with VS, MS and radiosurgery showed better local tumor control rates; however, compared with MS, different SRS all provided better protection of nerve function and improved the symptoms of vestibular function and tinnitus, among which the best was SRS."

This network meta-analysis supports radiosurgery as a treatment with tumor-control and nerve-function advantages in selected comparisons.

Proton Beam Radiation Therapy

Action: radiation therapy MAXO:0000014

Proton beam therapy has high reported tumor-control rates but does not clearly improve hearing or facial-nerve preservation compared with many modern stereotactic radiosurgery series.

Mechanism Target:

INHIBITS YAP TAZ TEAD-Driven Schwannoma Growth — Proton beam therapy is used to control tumor growth.

Show evidence (1 reference)

PMID:37402894 SUPPORT Human Clinical

"Proton beam therapy for VSs achieves high tumor control rates, as high as 95.4%."

This supports proton beam therapy as a radiation treatment with high tumor control in pooled studies.

Bevacizumab for NF2-Related Vestibular Schwannoma

Action: Pharmacotherapy NCIT:C15986

Agent: bevacizumab

Bevacizumab is an off-label anti-VEGF pharmacotherapy option for selected NF2-related vestibular schwannomas, with reported tumor-volume and hearing benefits in observational literature but frequent adverse events.

Mechanism Target:

INHIBITS VEGF-Mediated Angiogenesis — Bevacizumab targets VEGF-related tumor biology in NF2-related vestibular schwannoma.

Target Phenotypes: Hearing impairment ↗

Show evidence (2 references)

PMID:39685944 SUPPORT Human Clinical

"Bevacizumab showed a partial tumor volume reduction (≥20%) in 40% of cases and disease stabilization in 50%, while 10% experienced tumor progression."

This systematic review supports tumor-volume benefit and stabilization for bevacizumab in NF2-associated VS.

PMID:38672561 SUPPORT Human Clinical

"Following treatment, 40% of the patients experienced hearing improvement, 53%, stable hearing, and 7%, hearing loss."

This single-center series supports hearing benefit or stabilization in many bevacizumab-treated NF2-related schwannomatosis patients.

Lapatinib for NF2-Related Vestibular Schwannoma

Action: Pharmacotherapy NCIT:C15986

Agent: lapatinib

Lapatinib has been evaluated as a targeted therapy for vestibular schwannoma in NF2-related schwannomatosis; reported activity is modest compared with bevacizumab.

Show evidence (1 reference)

PMID:37706198 PARTIAL Human Clinical

"lapatinib had a RR of 6% and a HR of 31%."

This systematic review supports modest lapatinib radiographic and hearing response rates in NF2-related vestibular schwannoma.

Everolimus for Progressive NF2-Related Vestibular Schwannoma

Action: Pharmacotherapy NCIT:C15986

Agent: everolimus

Everolimus has been evaluated as mTORC1-directed pharmacotherapy for progressive NF2-related vestibular schwannoma; evidence supports possible growth-rate reduction but not objective radiographic response in the small phase II cohort.

Mechanism Target:

INHIBITS mTORC1 Signaling — Everolimus targets mTORC1 signaling downstream of NF2-related schwannoma biology.

Show evidence (1 reference)

PMID:38372904 PARTIAL Human Clinical

"After 52 weeks of treatment, the median annual VS growth rate decreased from 77.2% at baseline to 29.4%."

This supports possible growth-rate reduction but only partial treatment efficacy because the abstract also reports no radiographic response.

🧫

Experimental Models

1

NF2-null schwannoma primary-cell model PRIMARY_CELL_CULTURE

Human primary schwannoma cells were used to test YAP/TAZ-driven TEAD activity in NF2-null schwannoma growth.

Cell source

human primary tumor cells

Pathograph links

NF2 Merlin Tumor-Suppressor Loss

YAP TAZ TEAD-Driven Schwannoma Growth

Findings

YAP/TAZ-driven TEAD activity supports NF2-null schwannoma tumor growth.

"YAP/TAZ-driven signaling was identified in NF2-null schwannoma cells."

Show evidence (1 reference)

PMID:36148553 SUPPORT In Vitro

"driven by the TAZ protein in human and mouse NF2-null schwannoma cells"

This supports the primary-cell model as an in vitro system for NF2-null schwannoma signaling.

{ }

Source YAML

click to show

name: Acoustic Neuroma
creation_date: '2026-05-10T15:02:10Z'
updated_date: '2026-05-10T15:02:10Z'
category: Neoplastic
categories:
- Benign Neoplasm
- Peripheral Nerve Sheath Tumor
- Cranial Nerve Tumor
parents:
- schwannoma
synonyms:
- vestibular schwannoma
- acoustic schwannoma
- acoustic neurinoma
- acoustic neurilemmoma
disease_term:
  preferred_term: acoustic neuroma
  term:
    id: MONDO:0001569
    label: acoustic neuroma
description: >-
  Acoustic neuroma, also called vestibular schwannoma, is a benign
  Schwann-cell tumor of the vestibulocochlear nerve. Most tumors are unilateral
  and sporadic, while NF2-related schwannomatosis produces bilateral vestibular
  schwannomas and other nervous-system tumors. The main disease mechanisms are
  loss of NF2/merlin tumor-suppressor signaling in Schwann-lineage cells,
  downstream dysregulation of proliferation, motility, Hippo/YAP/TAZ-TEAD
  activity, and local tumor effects on cranial nerve VIII and adjacent
  posterior-fossa structures.
definitions:
- name: Vestibular schwannoma definition
  definition_type: CASE_DEFINITION
  description: >-
    Vestibular schwannoma is a benign tumor of neoplastic Schwann cells on the
    eighth cranial nerve.
  scope: General disease definition for acoustic neuroma / vestibular schwannoma
  evidence:
  - reference: PMID:38892775
    reference_title: "Vestibular Schwannoma and Tinnitus: A Systematic Review of Microsurgery Compared to Gamma Knife Radiosurgery."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Vestibular schwannoma (VS) is a benign tumor of the eighth cranial nerve formed from neoplastic Schwann cells."
    explanation: This systematic review abstract provides a concise disease-level definition.
has_subtypes:
- name: Sporadic Unilateral
  display_name: Sporadic Unilateral Acoustic Neuroma
  classification: clinical_context
  description: >-
    Most acoustic neuromas are unilateral sporadic tumors managed according to
    size, hearing status, symptoms, growth, and patient factors.
  evidence:
  - reference: PMID:39627752
    reference_title: "Treatment options for unilateral vestibular schwannoma: a network meta-analysis."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "This study aimed to explore the effect of observation, microsurgery, and radiotherapy for patients with vestibular schwannoma (VS)."
    explanation: This treatment network meta-analysis is explicitly scoped to unilateral VS, supporting a unilateral management context.
- name: NF2-Related
  display_name: NF2-Related Vestibular Schwannoma
  classification: genetic_context
  description: >-
    Vestibular schwannomas in NF2-related schwannomatosis are typically
    bilateral and occur as part of a genetic tumor-predisposition syndrome.
  evidence:
  - reference: PMID:38928264
    reference_title: "NF2-Related Schwannomatosis (NF2): Molecular Insights and Therapeutic Avenues."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "NF2-related schwannomatosis (NF2) is a genetic syndrome characterized by the growth of benign tumors in the nervous system, particularly bilateral vestibular schwannomas, meningiomas, and ependymomas."
    explanation: The review abstract directly supports bilateral vestibular schwannomas as a key NF2-related disease manifestation.
prevalence:
- population: Unilateral vestibular schwannoma clinical literature
  notes: >-
    The Falcon report identified recent epidemiology summaries reporting annual
    incidence around 10.4 per 100,000 in a 2024 treatment meta-analysis
    background and prevalence estimates of 3-5.2 per 100,000 person-years in a
    tinnitus-focused systematic review background. These exact figures are not
    quoted here because they were not present in the fetched PubMed abstracts.
progression:
- phase: Slow local growth with treatment-dependent functional outcomes
  notes: >-
    Acoustic neuroma is generally slow-growing, but tumor growth and active
    treatments can affect hearing, vestibular symptoms, facial nerve function,
    and trigeminal nerve function. Long-term hearing outcomes vary by treatment
    modality and pretreatment selection.
  evidence:
  - reference: PMID:39045727
    reference_title: "Long-Term Hearing Outcome For Vestibular Schwannomas After Microsurgery And Radiotherapy: A Systematic Review and Meta-Analysis."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Hearing loss is a common symptom associated with vestibular schwannoma (VS), either because of the tumor's effects on the cochlear nerve or due to active treatments such as surgery or stereotactic radiosurgery (SRS)."
    explanation: This supports the progressive and treatment-associated auditory outcome framing.
pathophysiology:
- name: NF2 Merlin Tumor-Suppressor Loss
  description: >-
    Loss or dysfunction of NF2/merlin is the central upstream molecular event in
    NF2-related vestibular schwannoma and a recurrent driver in schwannoma
    biology. Merlin normally coordinates contact, proliferation, and motility
    signals; loss of this restraint promotes tumorigenesis.
  cell_types:
  - preferred_term: Schwann cell
    term:
      id: CL:0002573
      label: Schwann cell
  genes:
  - preferred_term: NF2
    term:
      id: hgnc:7773
      label: NF2
  biological_processes:
  - preferred_term: cell cycle checkpoint signaling
    modifier: DECREASED
    term:
      id: GO:0000075
      label: cell cycle checkpoint signaling
  evidence:
  - reference: PMID:38928264
    reference_title: "NF2-Related Schwannomatosis (NF2): Molecular Insights and Therapeutic Avenues."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Merlin, a tumor suppressor, integrates multiple signaling pathways that regulate cell contact, proliferation, and motility, thereby influencing tumor growth."
    explanation: This supports merlin as a tumor suppressor coordinating processes relevant to schwannoma growth.
  - reference: PMID:38928264
    reference_title: "NF2-Related Schwannomatosis (NF2): Molecular Insights and Therapeutic Avenues."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "The loss of Merlin disrupts these pathways, leading to tumorigenesis."
    explanation: This directly supports the causal edge from merlin loss to tumor formation.
  downstream:
  - target: YAP TAZ TEAD-Driven Schwannoma Growth
    description: Merlin loss releases downstream Hippo/YAP/TAZ-TEAD proliferative programs.
- name: YAP TAZ TEAD-Driven Schwannoma Growth
  description: >-
    NF2-null schwannoma cells depend on Hippo-pathway effector activity,
    including YAP/TAZ-driven TEAD transcriptional output, to sustain tumor-cell
    growth. This mechanism is experimentally targetable in human primary tumor
    cells and mouse models.
  cell_types:
  - preferred_term: Schwann cell
    term:
      id: CL:0002573
      label: Schwann cell
  genes:
  - preferred_term: NF2
    term:
      id: hgnc:7773
      label: NF2
  biological_processes:
  - preferred_term: positive regulation of Schwann cell proliferation
    modifier: INCREASED
    term:
      id: GO:0010625
      label: positive regulation of Schwann cell proliferation
  evidence:
  - reference: PMID:36148553
    reference_title: Inhibition of YAP/TAZ-driven TEAD activity prevents growth of NF2-null schwannoma and meningioma.
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: "driven by the TAZ protein in human and mouse NF2-null schwannoma cells"
    explanation: This supports TAZ-driven signaling in NF2-null schwannoma cells.
  - reference: PMID:36148553
    reference_title: Inhibition of YAP/TAZ-driven TEAD activity prevents growth of NF2-null schwannoma and meningioma.
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: "successful use of TEAD palmitoylation inhibitors in a preclinical mouse model of schwannoma points to their potential future clinical use."
    explanation: This supports in vivo mouse-model evidence for TEAD inhibition as a schwannoma growth mechanism.
  downstream:
  - target: VEGF-Mediated Angiogenesis
    description: NF2-null schwannoma growth is linked to pro-angiogenic VEGF biology.
  - target: mTORC1 Signaling
    description: NF2-related schwannoma biology creates a rationale for mTORC1-directed therapy.
  - target: Vestibulocochlear Nerve Dysfunction
    description: Tumor growth on the eighth cranial nerve disrupts auditory and vestibular function.
- name: VEGF-Mediated Angiogenesis
  description: >-
    VEGF-related angiogenic signaling contributes to NF2-related vestibular
    schwannoma treatment biology and provides the mechanistic rationale for
    bevacizumab.
  biological_processes:
  - preferred_term: angiogenesis
    modifier: INCREASED
    term:
      id: GO:0001525
      label: angiogenesis
  evidence:
  - reference: PMID:39685944
    reference_title: "Bevacizumab for Vestibular Schwannomas in Neurofibromatosis Type 2: A Systematic Review of Tumor Control and Hearing Preservation."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Bevacizumab, a VEGF-targeting monoclonal antibody, has emerged as a less invasive treatment option, showing potential for tumor volume reduction and hearing preservation."
    explanation: This supports VEGF as the treatment-linked angiogenic mechanism targeted by bevacizumab in NF2-related VS.
- name: mTORC1 Signaling
  description: >-
    mTORC1 signaling is implicated as a downstream actionable pathway in
    progressive NF2-related vestibular schwannoma, motivating everolimus therapy.
  biological_processes:
  - preferred_term: TOR signaling
    modifier: INCREASED
    term:
      id: GO:0031929
      label: TOR signaling
  evidence:
  - reference: PMID:38372904
    reference_title: Imaging as an early biomarker to predict sensitivity to everolimus for progressive NF2-related vestibular schwannoma.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Pre-clinical studies highlighted the potential of mTORC1 inhibition in delaying schwannoma progression."
    explanation: This supports mTORC1 signaling as the mechanism targeted by everolimus in progressive NF2-related VS.
- name: Vestibulocochlear Nerve Dysfunction
  description: >-
    Tumor growth along cranial nerve VIII and in the internal auditory
    canal/cerebellopontine-angle region impairs auditory and vestibular
    signaling; larger tumors can affect adjacent cranial nerves and posterior
    fossa structures.
  locations:
  - preferred_term: vestibulocochlear nerve
    term:
      id: UBERON:0001648
      label: vestibulocochlear nerve
  - preferred_term: cerebellopontine angle
    term:
      id: UBERON:0014908
      label: cerebellopontine angle
  evidence:
  - reference: PMID:38892775
    reference_title: "Vestibular Schwannoma and Tinnitus: A Systematic Review of Microsurgery Compared to Gamma Knife Radiosurgery."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Although VS can cause a variety of symptoms, tinnitus is one of the most distressing symptoms for patients and can greatly impact quality of life."
    explanation: This supports symptomatic auditory morbidity from vestibular schwannoma.
  downstream:
  - target: Sensorineural Hearing Impairment
    description: Cochlear nerve involvement produces hearing impairment.
  - target: Tinnitus
    description: Eighth-nerve tumor effects can produce persistent tinnitus.
  - target: Vestibular Symptoms
    description: Vestibular nerve involvement produces vertigo or disequilibrium.
phenotypes:
- name: Sensorineural Hearing Impairment
  description: >-
    Hearing impairment is one of the most common and functionally important
    manifestations of acoustic neuroma and may reflect tumor effects on the
    cochlear nerve or treatment effects.
  phenotype_term:
    preferred_term: Hearing impairment
    term:
      id: HP:0000365
      label: Hearing impairment
    clinical_course: PROGRESSIVE
  evidence:
  - reference: PMID:39045727
    reference_title: "Long-Term Hearing Outcome For Vestibular Schwannomas After Microsurgery And Radiotherapy: A Systematic Review and Meta-Analysis."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Hearing loss is a common symptom associated with vestibular schwannoma (VS), either because of the tumor's effects on the cochlear nerve or due to active treatments such as surgery or stereotactic radiosurgery (SRS)."
    explanation: This directly supports hearing loss as a common acoustic-neuroma manifestation.
- name: Tinnitus
  description: >-
    Tinnitus can be persistent, distressing, and quality-of-life limiting in
    patients with vestibular schwannoma.
  phenotype_term:
    preferred_term: Tinnitus
    term:
      id: HP:0000360
      label: Tinnitus
  evidence:
  - reference: PMID:38892775
    reference_title: "Vestibular Schwannoma and Tinnitus: A Systematic Review of Microsurgery Compared to Gamma Knife Radiosurgery."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Although VS can cause a variety of symptoms, tinnitus is one of the most distressing symptoms for patients and can greatly impact quality of life."
    explanation: This directly supports tinnitus as a clinically important VS symptom.
- name: Headache
  description: >-
    Headache is a common presenting symptom in clinical acoustic-neuroma cohorts,
    likely reflecting posterior-fossa mass effect or associated intracranial
    pressure effects in some patients.
  phenotype_term:
    preferred_term: Headache
    term:
      id: HP:0002315
      label: Headache
  evidence:
  - reference: DOI:10.37897/rjn.2024.3.7
    reference_title: "Current trends in vestibular schwannoma management at a referral center in Indonesia: A cross-sectional study with retrospective data collection"
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Common symptoms included hearing loss (63.6%), disequilibrium (50%), and headaches (39.7%)."
    explanation: This retrospective cohort directly supports headache as a common acoustic-neuroma symptom.
- name: Vestibular Symptoms
  description: >-
    Disequilibrium and vertigo are common vestibular manifestations and are
    treatment-relevant outcomes in unilateral vestibular schwannoma.
  phenotype_term:
    preferred_term: Vertigo or disequilibrium
    term:
      id: HP:0002321
      label: Vertigo
  evidence:
  - reference: PMID:39627752
    reference_title: "Treatment options for unilateral vestibular schwannoma: a network meta-analysis."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "In terms of improving the rate of disequilibrium/vertigo, the order from the highest to the lowest was SRS, Observation, FSRT 3 fractions, FSRT 5 fractions, MS, and ConFSRT."
    explanation: This supports disequilibrium/vertigo as a tracked clinical outcome in unilateral VS treatment studies.
- name: Facial Nerve Dysfunction
  description: >-
    Facial nerve dysfunction can occur from tumor mass effect, treatment
    morbidity, or both; facial nerve preservation is a major treatment outcome.
  phenotype_term:
    preferred_term: Facial nerve dysfunction
  evidence:
  - reference: PMID:37402894
    reference_title: "Proton beam radiation therapy for vestibular schwannomas-tumor control and hearing preservation rates: a systematic review and meta-analysis."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Here, we performed a systematic review and meta-analysis of proton beam for VSs, evaluating tumor control and cranial nerve preservation rates, particularly with regard to facial and hearing preservation."
    explanation: This supports facial nerve function as a clinically important cranial-nerve outcome in VS.
- name: Trigeminal Nerve Dysfunction
  description: >-
    Trigeminal sensory symptoms are a treatment-relevant cranial-nerve outcome
    in unilateral vestibular schwannoma.
  phenotype_term:
    preferred_term: Trigeminal nerve dysfunction
  evidence:
  - reference: PMID:39627752
    reference_title: "Treatment options for unilateral vestibular schwannoma: a network meta-analysis."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "In terms of protection of the trigeminal nerve, the order from the highest to lowest was observation, SRS, ConFSRT, FSRT 3 fractions, FSRT 5 fractions, and MS."
    explanation: This supports trigeminal nerve dysfunction risk as an outcome considered in treatment comparisons.
genetic:
- name: NF2 loss or dysfunction
  gene_term:
    preferred_term: NF2
    term:
      id: hgnc:7773
      label: NF2
  association: Causal tumor suppressor gene in NF2-related disease and a key schwannoma driver.
  relationship_type: CAUSATIVE
  variant_origin: GERMLINE_AND_SOMATIC
  evidence:
  - reference: PMID:38928264
    reference_title: "NF2-Related Schwannomatosis (NF2): Molecular Insights and Therapeutic Avenues."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "This review consolidates the current knowledge on NF2 syndrome, emphasizing the molecular pathology associated with the mutations in the gene of the same name, the NF2 gene, and the subsequent dysfunction of its product, the Merlin protein."
    explanation: This supports NF2 mutation and merlin dysfunction as central molecular pathology.
diagnosis:
- name: Contrast-enhanced MRI
  description: >-
    MRI, often with contrast, is the key imaging modality for detecting and
    monitoring acoustic neuroma / vestibular schwannoma.
  diagnosis_term:
    preferred_term: magnetic resonance imaging procedure
    term:
      id: MAXO:0000424
      label: magnetic resonance imaging procedure
  results: MRI identifies the vestibular schwannoma and supports volumetric monitoring during observation or treatment.
  evidence:
  - reference: PMID:38372904
    reference_title: Imaging as an early biomarker to predict sensitivity to everolimus for progressive NF2-related vestibular schwannoma.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Brain imaging was obtained quarterly."
    explanation: This prospective NF2-related VS trial supports serial brain imaging as a monitoring method for progressive VS.
- name: Audiologic monitoring
  description: >-
    Pure-tone audiometry and word-recognition testing are used to track hearing
    status and treatment response.
  diagnosis_term:
    preferred_term: audiologic monitoring
  results: Hearing outcomes are commonly expressed as serviceable hearing, word recognition score, or pure-tone thresholds.
  evidence:
  - reference: PMID:38372904
    reference_title: Imaging as an early biomarker to predict sensitivity to everolimus for progressive NF2-related vestibular schwannoma.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Secondary endpoints included other tumors RR, hearing outcomes, drug safety and quality of life (QOL)."
    explanation: This supports formal hearing outcomes as part of VS treatment assessment.
treatments:
- name: Observation
  description: >-
    Observation is a standard management option for selected unilateral tumors,
    especially when symptoms, size, growth, and patient factors favor
    surveillance over immediate intervention.
  treatment_term:
    preferred_term: observation
  evidence:
  - reference: PMID:39627752
    reference_title: "Treatment options for unilateral vestibular schwannoma: a network meta-analysis."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "This study aimed to explore the effect of observation, microsurgery, and radiotherapy for patients with vestibular schwannoma (VS)."
    explanation: This supports observation as one of the treatment strategies compared for unilateral VS.
- name: Microsurgical Resection
  description: >-
    Microsurgery offers tumor removal and local control but must be balanced
    against risks to hearing and adjacent cranial nerves.
  treatment_term:
    preferred_term: surgical procedure
    term:
      id: MAXO:0000004
      label: surgical procedure
  target_phenotypes:
  - preferred_term: Hearing impairment
    term:
      id: HP:0000365
      label: Hearing impairment
  target_mechanisms:
  - target: YAP TAZ TEAD-Driven Schwannoma Growth
    treatment_effect: INHIBITS
    description: Microsurgical tumor removal directly reduces tumor burden.
  evidence:
  - reference: PMID:39045727
    reference_title: "Long-Term Hearing Outcome For Vestibular Schwannomas After Microsurgery And Radiotherapy: A Systematic Review and Meta-Analysis."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Microsurgery demonstrated a higher prevalence of maintaining long-term serviceable hearing, with a pooled estimate of 74.5% (95% CI: 63.5%-84.1%)."
    explanation: This supports microsurgery as an active VS treatment with reported long-term hearing-preservation outcomes in selected cohorts.
- name: Stereotactic Radiosurgery
  description: >-
    Stereotactic radiosurgery is an active tumor-control strategy for selected
    acoustic neuromas and may preserve nerve function better than microsurgery
    in some treatment comparisons.
  treatment_term:
    preferred_term: stereotactic radiosurgery
    term:
      id: MAXO:0009088
      label: stereotactic radiosurgery
  target_phenotypes:
  - preferred_term: Vertigo or disequilibrium
    term:
      id: HP:0002321
      label: Vertigo
  target_mechanisms:
  - target: YAP TAZ TEAD-Driven Schwannoma Growth
    treatment_effect: INHIBITS
    description: Stereotactic radiosurgery is used to control tumor growth.
  evidence:
  - reference: PMID:39627752
    reference_title: "Treatment options for unilateral vestibular schwannoma: a network meta-analysis."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "In patients with VS, MS and radiosurgery showed better local tumor control rates; however, compared with MS, different SRS all provided better protection of nerve function and improved the symptoms of vestibular function and tinnitus, among which the best was SRS."
    explanation: This network meta-analysis supports radiosurgery as a treatment with tumor-control and nerve-function advantages in selected comparisons.
- name: Proton Beam Radiation Therapy
  description: >-
    Proton beam therapy has high reported tumor-control rates but does not
    clearly improve hearing or facial-nerve preservation compared with many
    modern stereotactic radiosurgery series.
  treatment_term:
    preferred_term: radiation therapy
    term:
      id: MAXO:0000014
      label: radiation therapy
  target_mechanisms:
  - target: YAP TAZ TEAD-Driven Schwannoma Growth
    treatment_effect: INHIBITS
    description: Proton beam therapy is used to control tumor growth.
  evidence:
  - reference: PMID:37402894
    reference_title: "Proton beam radiation therapy for vestibular schwannomas-tumor control and hearing preservation rates: a systematic review and meta-analysis."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Proton beam therapy for VSs achieves high tumor control rates, as high as 95.4%."
    explanation: This supports proton beam therapy as a radiation treatment with high tumor control in pooled studies.
- name: Bevacizumab for NF2-Related Vestibular Schwannoma
  description: >-
    Bevacizumab is an off-label anti-VEGF pharmacotherapy option for selected
    NF2-related vestibular schwannomas, with reported tumor-volume and hearing
    benefits in observational literature but frequent adverse events.
  context: NF2-related vestibular schwannoma
  treatment_term:
    preferred_term: Pharmacotherapy
    term:
      id: NCIT:C15986
      label: Pharmacotherapy
    therapeutic_agent:
    - preferred_term: bevacizumab
  target_phenotypes:
  - preferred_term: Hearing impairment
    term:
      id: HP:0000365
      label: Hearing impairment
  target_mechanisms:
  - target: VEGF-Mediated Angiogenesis
    treatment_effect: INHIBITS
    description: Bevacizumab targets VEGF-related tumor biology in NF2-related vestibular schwannoma.
  evidence:
  - reference: PMID:39685944
    reference_title: "Bevacizumab for Vestibular Schwannomas in Neurofibromatosis Type 2: A Systematic Review of Tumor Control and Hearing Preservation."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Bevacizumab showed a partial tumor volume reduction (≥20%) in 40% of cases and disease stabilization in 50%, while 10% experienced tumor progression."
    explanation: This systematic review supports tumor-volume benefit and stabilization for bevacizumab in NF2-associated VS.
  - reference: PMID:38672561
    reference_title: "Bevacizumab Treatment for Patients with NF2-Related Schwannomatosis: A Single Center Experience."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Following treatment, 40% of the patients experienced hearing improvement, 53%, stable hearing, and 7%, hearing loss."
    explanation: This single-center series supports hearing benefit or stabilization in many bevacizumab-treated NF2-related schwannomatosis patients.
- name: Lapatinib for NF2-Related Vestibular Schwannoma
  description: >-
    Lapatinib has been evaluated as a targeted therapy for vestibular schwannoma
    in NF2-related schwannomatosis; reported activity is modest compared with
    bevacizumab.
  context: NF2-related vestibular schwannoma
  treatment_term:
    preferred_term: Pharmacotherapy
    term:
      id: NCIT:C15986
      label: Pharmacotherapy
    therapeutic_agent:
    - preferred_term: lapatinib
  evidence:
  - reference: PMID:37706198
    reference_title: A systematic review of targeted therapy for vestibular schwannoma in patients with NF2-related schwannomatosis.
    supports: PARTIAL
    evidence_source: HUMAN_CLINICAL
    snippet: "lapatinib had a RR of 6% and a HR of 31%."
    explanation: This systematic review supports modest lapatinib radiographic and hearing response rates in NF2-related vestibular schwannoma.
- name: Everolimus for Progressive NF2-Related Vestibular Schwannoma
  description: >-
    Everolimus has been evaluated as mTORC1-directed pharmacotherapy for
    progressive NF2-related vestibular schwannoma; evidence supports possible
    growth-rate reduction but not objective radiographic response in the small
    phase II cohort.
  context: Progressive NF2-related vestibular schwannoma
  treatment_term:
    preferred_term: Pharmacotherapy
    term:
      id: NCIT:C15986
      label: Pharmacotherapy
    therapeutic_agent:
    - preferred_term: everolimus
  target_mechanisms:
  - target: mTORC1 Signaling
    treatment_effect: INHIBITS
    description: Everolimus targets mTORC1 signaling downstream of NF2-related schwannoma biology.
  evidence:
  - reference: PMID:38372904
    reference_title: Imaging as an early biomarker to predict sensitivity to everolimus for progressive NF2-related vestibular schwannoma.
    supports: PARTIAL
    evidence_source: HUMAN_CLINICAL
    snippet: "After 52 weeks of treatment, the median annual VS growth rate decreased from 77.2% at baseline to 29.4%."
    explanation: This supports possible growth-rate reduction but only partial treatment efficacy because the abstract also reports no radiographic response.
animal_models:
- species: mouse
  genotype: Periostin-Cre NF2fl/fl schwannoma model
  category: Genetically engineered mouse model
  genes:
  - preferred_term: NF2
    term:
      id: hgnc:7773
      label: NF2
  description: >-
    Mouse schwannoma models were used to test YAP/TAZ ablation and TEAD
    palmitoylation inhibitors in vivo.
  associated_phenotypes:
  - Schwannoma tumor growth
  evidence:
  - reference: PMID:36148553
    reference_title: Inhibition of YAP/TAZ-driven TEAD activity prevents growth of NF2-null schwannoma and meningioma.
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: "successful use of TEAD palmitoylation inhibitors in a preclinical mouse model of schwannoma points to their potential future clinical use."
    explanation: This directly documents the mouse-model component of the preclinical mechanism study.
experimental_models:
- name: NF2-null schwannoma primary-cell model
  description: >-
    Human primary schwannoma cells were used to test YAP/TAZ-driven TEAD
    activity in NF2-null schwannoma growth.
  experimental_model_type: PRIMARY_CELL_CULTURE
  cell_types:
  - preferred_term: Schwann cell
    term:
      id: CL:0002573
      label: Schwann cell
  conditions:
  - NF2-null schwannoma cells
  cell_source: human primary tumor cells
  modeled_mechanisms:
  - target: NF2 Merlin Tumor-Suppressor Loss
  - target: YAP TAZ TEAD-Driven Schwannoma Growth
  findings:
  - statement: YAP/TAZ-driven TEAD activity supports NF2-null schwannoma tumor growth.
    supporting_text: >-
      YAP/TAZ-driven signaling was identified in NF2-null schwannoma cells.
  evidence:
  - reference: PMID:36148553
    reference_title: Inhibition of YAP/TAZ-driven TEAD activity prevents growth of NF2-null schwannoma and meningioma.
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: "driven by the TAZ protein in human and mouse NF2-null schwannoma cells"
    explanation: This supports the primary-cell model as an in vitro system for NF2-null schwannoma signaling.
notes: >-
  Falcon deep research was completed on 2026-05-10 and saved in
  research/Acoustic_Neuroma-deep-research-falcon.md with citations in the
  adjacent .citations.md file. Several additional terms from the report were
  intentionally left as preferred_term-only because OAK lookups were slow or
  inconclusive during batch curation.

📚

References & Deep Research

Deep Research

1

Falcon ▸

1. Disease Information

Edison Scientific Literature 47 citations 2026-05-10T11:17:15.413079

1. Disease Information

1.1 Overview (current understanding)

Acoustic neuroma is the common clinical name for vestibular schwannoma (VS), a benign Schwann-cell tumor that arises on the vestibulocochlear nerve (cranial nerve VIII), typically in the cerebellopontine angle/internal auditory canal region, and can cause hearing loss, tinnitus, and balance symptoms. (screnci2024bevacizumabforvestibular pages 1-2, huo2024treatmentoptionsfor pages 1-2)

Synonyms / alternative names (from retrieved sources): - Vestibular schwannoma (VS) (huo2024treatmentoptionsfor pages 1-2, screnci2024bevacizumabforvestibular pages 1-2) - Acoustic neuroma (huo2024treatmentoptionsfor pages 1-2, screnci2024bevacizumabforvestibular pages 1-2)

1.2 Key identifiers

MONDO ID: not available from retrieved sources.
MeSH / ICD-10 / ICD-11 / OMIM / Orphanet: not available from retrieved sources.

1.3 Evidence source type

The information below is derived from: - Aggregated disease-level resources: systematic reviews/meta-analyses and reviews (e.g., BMC Cancer 2024 network meta-analysis; J Clin Med 2024 systematic review; Neurosurg Rev 2023 meta-analysis; IJMS 2024 review). (huo2024treatmentoptionsfor pages 1-2, screnci2024bevacizumabforvestibular pages 1-2, santacroce2023protonbeamradiation pages 1-2, kim2024nf2relatedschwannomatosis(nf2) pages 1-2) - Single-center/retrospective clinical cohorts (e.g., an 88-patient Indonesian series). (aman2024currenttrendsin pages 5-6, aman2024currenttrendsin pages 1-2) - Primary preclinical mechanistic studies (e.g., Brain 2023 Hippo/TEAD targeting). (laraba2023inhibitionofyaptazdriven pages 1-2)

2. Etiology

2.1 Disease causal factors

Genetic/mechanistic (core driver): NF2 loss (merlin deficiency). Schwannomas are reported to be “mostly caused by loss of the tumour suppressor Merlin (NF2)”. (laraba2023inhibitionofyaptazdriven pages 1-2)

Syndromic etiology: NF2-associated vestibular schwannomas are commonly bilateral and are attributed to autosomal dominant pathogenic variants in NF2 (chromosome 22), encoding merlin. (screnci2024bevacizumabforvestibular pages 1-2, kim2024nf2relatedschwannomatosis(nf2) pages 1-2)

2.2 Risk factors

NF2-related schwannomatosis (genetic) risk: - NF2-related schwannomatosis prevalence and inheritance features are summarized in the 2024 review: autosomal dominant; approximately half inherited; among de novo cases, 25–50% mosaicism. (kim2024nf2relatedschwannomatosis(nf2) pages 1-2)

Sporadic VS epidemiology context: Up to 95% of VS are reported as unilateral/sporadic in a 2024 systematic review background. (king2024vestibularschwannomaand pages 1-2)

Environmental/lifestyle risk factors: high-quality causal environmental risk factor evidence is not established in the retrieved texts. One Mendelian-randomization analysis was retrieved (as background evidence of genetically predicted exposures), but it does not provide established clinical risk-factor guidance in the excerpts available. ( is not available; MR paper presence noted in retrieval but not in citeable evidence set beyond initial search list)

2.3 Protective factors

No clinically established protective factors with quantitative effects were available in the retrieved excerpts for VS specifically.

2.4 Gene–environment interaction

No gene–environment interaction results were available in the retrieved excerpts.

3. Phenotypes

3.1 Core clinical phenotypes (with characteristics and frequencies)

Typical symptom domains include hearing loss, tinnitus, and vestibular symptoms; larger tumors can produce hydrocephalus/brainstem compression and cranial neuropathies. (huo2024treatmentoptionsfor pages 1-2)

Quantitative phenotype frequencies (recent real-world cohort, 2018–2023; n=88): - Hearing loss: 63.6% (aman2024currenttrendsin pages 1-2) - Disequilibrium: 50% (aman2024currenttrendsin pages 1-2) - Headache: 39.7% (aman2024currenttrendsin pages 1-2)

Quantitative phenotype frequencies (same center; additional cohort summary with broader symptom listing): - Hearing loss: 71.5% - Disequilibrium: 50% - Headache: 39.7% - Tinnitus: 25% - Facial nerve palsy: 25% - Trigeminal deficits: 20.4% (Short mean follow-up for treated subgroup noted in the paper; interpret as baseline presentation frequencies in a tertiary-care cohort.) (aman2024currenttrendsin pages 5-6)

Systematic review background symptom statement: “More than 60%” of patients have progressive hearing loss and tinnitus. (huo2024treatmentoptionsfor pages 1-2)

3.2 Quality of life impact

Tinnitus is repeatedly emphasized as distressing and QoL-limiting. In a 2024 systematic review on tinnitus outcomes, 36.6% had at least one episode of tinnitus distress (THI>18), and mean THI decreased from 15.8 preoperatively to 10.1 postoperatively at mean follow-up ~34.7 months. (king2024vestibularschwannomaand pages 4-5)

3.3 HPO term suggestions (phenotype normalization)

Suggested HPO terms (as a starting mapping set; confirm exact term IDs in HPO browser during curation): - Hearing loss: HP:0000365 (aman2024currenttrendsin pages 5-6) - Tinnitus: HP:0000360 (aman2024currenttrendsin pages 5-6) - Vertigo/disequilibrium/dizziness: HP:0002321 / HP:0002329 (aman2024currenttrendsin pages 5-6) - Headache: HP:0002315 (aman2024currenttrendsin pages 5-6) - Facial palsy/weakness: HP:0000490 (aman2024currenttrendsin pages 5-6) - Trigeminal sensory deficit/facial numbness: HP:0003407 (aman2024currenttrendsin pages 5-6)

4. Genetic/Molecular Information

4.1 Causal genes

NF2 (merlin) is the core tumor suppressor gene implicated in NF2-related disease and in schwannoma biology; the 2024 NF2 review places NF2 at 22q12.2. (kim2024nf2relatedschwannomatosis(nf2) pages 1-2)

4.2 Molecular pathways and cellular processes (current understanding)

Merlin function and loss-of-function consequences: merlin is described as a FERM-domain membrane–cytoskeleton scaffolding tumor suppressor (enriched in Schwann cells/adherens junctions) integrating signals controlling proliferation and motility; its loss promotes tumorigenesis. (kim2024nf2relatedschwannomatosis(nf2) pages 1-2)

Hippo/YAP/TAZ signaling as a central downstream axis: - Preclinical evidence (2023): “Using both genetic ablation of the Hippo effectors YAP and TAZ as well as novel TEAD palmitoylation inhibitors, we show that Hippo signalling may be successfully targeted in vitro and in vivo to both block and…regress schwannoma tumour growth.” (direct abstract quote) (laraba2023inhibitionofyaptazdriven pages 1-2) - The study also identifies ALDH1A1 as a TAZ-driven Hippo target in NF2-null schwannoma cells. (laraba2023inhibitionofyaptazdriven pages 1-2)

Angiogenesis (VEGF) and signaling cross-talk: a 2024 immune-microenvironment review describes a causal chain in which VEGF/VEGFR2 activates PI3K–AKT and MEK–ERK, suppresses Hippo kinases (Mst1/2; Lats1/2), and promotes YAP/TAZ-driven programs; merlin loss contributes to constitutive YAP/TAZ-mediated VEGF angiogenesis. (jones2024deconvolvingtheimmunea pages 35-39)

mTOR pathway and targeted inhibition rationale: - A phase II everolimus trial is motivated by preclinical findings that “mTORC1 inhibition” may delay schwannoma progression (summarized within the clinical paper). (nghiemphu2024imagingasan pages 1-2)

4.3 Epigenetics / multi-omics

No quantitative epigenetic methylation signatures or multi-omics datasets for VS were extractable from the retrieved excerpts, although mechanistic reviews discuss pathway-level regulation and emerging molecular therapies. (kim2024nf2relatedschwannomatosis(nf2) pages 6-7, kim2024nf2relatedschwannomatosis(nf2) pages 1-2)

4.4 GO and CL term suggestions (mechanism annotation)

Proposed GO biological process terms for curation (validate with GO browser): - Hippo signaling: GO:0035329 (Hippo signaling) - Regulation of cell proliferation: GO:0042127 - Angiogenesis: GO:0001525 - PI3K signaling: GO:0014065 (phosphatidylinositol 3-kinase signaling) - mTOR signaling: GO:0031929 (TOR signaling)

Proposed CL cell types: - Schwann cell: CL:0000218 (primary tumor lineage)

5. Environmental Information

No specific toxins, infectious triggers, or validated lifestyle risk/protective factors for VS were established in the retrieved excerpts. General audiovestibular symptom epidemiology in non-VS populations was retrieved but is not disease-specific evidence for VS etiologic inference. ( not citeable; not in evidence set)

6. Mechanism / Pathophysiology

6.1 Causal chain (integrated model)

1) Initiating event: NF2/merlin loss (germline/mosaic in NF2-related schwannomatosis; somatic in sporadic schwannoma) in Schwann lineage. (kim2024nf2relatedschwannomatosis(nf2) pages 1-2, laraba2023inhibitionofyaptazdriven pages 1-2) 2) Pathway dysregulation: derepression of Hippo effector activity (YAP/TAZ → TEAD transcriptional programs) and coupling to proliferative and angiogenic signaling (VEGF/VEGFR2 → PI3K/AKT, MEK/ERK; suppression of Hippo core kinases). (laraba2023inhibitionofyaptazdriven pages 1-2, jones2024deconvolvingtheimmunea pages 35-39) 3) Tissue/organ-level effects: tumor growth along CN VIII and adjacent cranial nerves in the cerebellopontine angle/internal auditory canal causes cochlear nerve dysfunction (hearing loss), aberrant auditory perception (tinnitus), vestibular dysfunction (disequilibrium/vertigo), and—if larger—mass effect with hydrocephalus/brainstem compression and cranial neuropathies (CN V/VII). (huo2024treatmentoptionsfor pages 1-2, aman2024currenttrendsin pages 5-6)

6.2 Upstream vs downstream

Upstream: merlin loss (NF2), VEGF/VEGFR2 activation, TGFβ axis changes (TGFβR2 loss/TGFβR1 upregulation described in review). (jones2024deconvolvingtheimmunea pages 35-39)
Downstream: YAP/TAZ–TEAD transcriptional output; tumor proliferation/survival; angiogenesis; cranial nerve dysfunction from local compression/invasion. (laraba2023inhibitionofyaptazdriven pages 1-2, huo2024treatmentoptionsfor pages 1-2)

7. Anatomical Structures Affected

7.1 Organ/tissue level

Primary site: vestibulocochlear nerve (CN VIII) / cerebellopontine angle region. (screnci2024bevacizumabforvestibular pages 1-2, huo2024treatmentoptionsfor pages 1-2)
Secondary/adjacent structures: facial nerve (CN VII), trigeminal nerve (CN V), brainstem, ventricular system (hydrocephalus). (huo2024treatmentoptionsfor pages 1-2, aman2024currenttrendsin pages 5-6)

7.2 UBERON suggestions

Vestibulocochlear nerve (UBERON term to be confirmed in ontology browser)
Cerebellopontine angle (UBERON term to be confirmed)

7.3 Lateralization

Most cases are unilateral/sporadic, while NF2-associated disease is commonly bilateral. (king2024vestibularschwannomaand pages 1-2, screnci2024bevacizumabforvestibular pages 1-2)

8. Temporal Development

8.1 Onset and progression

VS is described as a slowly growing benign tumor with clinical impact evolving as auditory/vestibular symptoms and, for larger tumors, mass effect. (screnci2024bevacizumabforvestibular pages 1-2, huo2024treatmentoptionsfor pages 1-2)

NF2-related schwannomatosis: adults often present with hearing loss and balance disturbance; pediatric cases may show other early signs. (kim2024nf2relatedschwannomatosis(nf2) pages 1-2)

8.2 Staging / grading

A management review excerpt references use of Koos grading (I–IV) for tumor-size-based decision making (not fully detailed in the excerpt). (jones2024deconvolvingtheimmunea pages 35-39)

9. Inheritance and Population

9.1 Epidemiology (VS)

VS reported as ~8% of intracranial tumors and most common cerebellopontine angle tumor. (huo2024treatmentoptionsfor pages 1-2)
Reported annual incidence 10.4 per 100,000 (in background of 2024 network meta-analysis). (huo2024treatmentoptionsfor pages 1-2)
A 2024 tinnitus-focused systematic review background states VS prevalence 3–5.2 per 100,000 person-years, and up to 95% are unilateral/sporadic. (king2024vestibularschwannomaand pages 1-2)

9.2 NF2-related schwannomatosis (inheritance)

Autosomal dominant, caused by germline or mosaic NF2 variants (22q12.2). (kim2024nf2relatedschwannomatosis(nf2) pages 1-2)
Prevalence ~1:50,000; birth incidence ~1:28,000. (kim2024nf2relatedschwannomatosis(nf2) pages 1-2)
~50% inherited; among de novo, 25–50% mosaicism. (kim2024nf2relatedschwannomatosis(nf2) pages 1-2)

10. Diagnostics

10.1 Imaging

A 2024 AI-in-AN systematic review states CT and MRI are preferred imaging modalities; gadolinium contrast improves visualization; typical MRI signal characteristics are described (T1 iso/hypointense; heterogeneous hyperintense T2). (alsaleh2024theimpactof pages 1-3)
NF2-related disease diagnosis and monitoring: MRI emphasized as key neuroimaging tool. (kim2024nf2relatedschwannomatosis(nf2) pages 1-2)

10.2 Audiology and electrophysiology

Hearing outcomes and monitoring often use pure-tone audiometry (PTA) and word recognition score (WRS); one NF2 bevacizumab series pre-specified hearing change as ≥10% WRS or ≥10 dB PTA thresholds. (douwes2024bevacizumabtreatmentfor pages 2-4)
Intraoperative monitoring: brainstem auditory evoked potentials (BAEPs) are commonly used; a 2024 cohort (n=127) introduced standardized BAEP indices using the contralateral healthy side reference to improve prediction of postoperative hearing preservation. ( not citeable; not in current evidence set)

10.3 Emerging/real-world implementations (2023–2024)

AI applications: models for segmentation, volume estimation, radiomics, decision support, QoL evaluation, and treatment planning are being developed, but standardization and external validation remain key needs. (alsaleh2024theimpactof pages 1-3)

10.4 Differential diagnosis

Not systematically extractable from the current evidence excerpts.

11. Outcome / Prognosis

11.1 Treatment-associated functional outcomes (hearing)

Long-term serviceable hearing after SRS: pooled 18.1% at 10 years (wide CI). (daloiso2024long‐termhearingoutcome pages 1-2)
Long-term serviceable hearing after microsurgery in selected hearing-preservation cohorts: pooled 74.5% at 10 years. (daloiso2024long‐termhearingoutcome pages 1-2)

11.2 Morbidity/QoL

Tinnitus distress burden and its improvement after interventions have been quantified by THI changes in recent systematic review data. (king2024vestibularschwannomaand pages 4-5)

12. Treatment

12.1 Treatment strategy (current practice)

A 2024 network meta-analysis frames VS management options as: - Observation - Microsurgery (MS) - Radiotherapy, including SRS and fractionated stereotactic radiotherapy (FSRT/ConFSRT) (PQ evidence indicates decision-making depends on tumor size, symptoms, and preference.) (huo2024treatmentoptionsfor pages 1-2)

12.2 Radiotherapy/radiosurgery outcomes

CyberKnife radiosurgery hearing preservation: pooled 68% (95% CI 59–76%) at mean follow-up ~43 months among patients with serviceable hearing pre-treatment (systematic review of 13 studies/493 participants). (tavares2024hearingfunctionafter pages 1-2)
Proton beam therapy (meta-analysis, 587 patients): tumor control 95.4%, progression 4.6%, facial nerve preservation 93.7%, hearing preservation 40.6%, shunt for hydrocephalus 1.4%. (santacroce2023protonbeamradiation pages 1-2)
SRS tumor control reported as 90–98% at 10 years in a 2024 review/meta-analysis summary. (pontillo2024hearingpreservationsurgery pages 1-2)

12.3 Surgery outcomes

Reported broadly as <25% hearing preservation overall in a 2024 hearing-preservation surgery meta-analysis summary (noting heterogeneity and limitations), while SRT ~50% (long-term SRT data limited). (pontillo2024hearingpreservationsurgery pages 1-2)
A tinnitus-focused systematic review background reports surgical mortality 0.38% and overall complication rate 5.3% (contextual figures rather than modality-stratified modern series outcomes). (king2024vestibularschwannomaand pages 1-2)

12.4 Pharmacotherapy / targeted therapy (NF2-related VS)

Bevacizumab (anti-VEGF; off-label use in NF2-related VS): - Systematic review (9 studies; n=176): tumor volume reduction ≥20% 40%, stabilization 50%, progression 10%; hearing improvement 36%, stabilization 46%, deterioration 18%; severe adverse events 13%. (screnci2024bevacizumabforvestibular pages 1-2) - Single-center experience (n=17): hearing improvement 40%, stable 53%, hearing loss 7%; tumor regression 31%, stable 69%; discontinuation for adverse events 29%; hypertension 82%, fatigue 29%. (douwes2024bevacizumabtreatmentfor pages 13-14)

Everolimus (mTORC1 inhibitor): - 2024 prospective open-label phase II report (NCT01345136; n=12): “After 52 weeks of treatment, the median annual VS growth rate decreased from 77.2% at baseline to 29.4%.” (direct abstract quote) There was no radiographic response, and 3/8 (37.5%) had stable disease; 3-month volumetric imaging predicted 12-month stabilization. (nghiemphu2024imagingasan pages 1-2) - ClinicalTrials.gov record NCT01345136: phase II monotherapy trial was terminated for slow accrual; planned primary endpoint was MRI volumetric change at 1 year. (NCT01345136 chunk 1)

Other targeted agents (systematic review through Oct 2022): - Lapatinib: hearing response 31% (4/13); radiographic response 6% (1/17); median TTP ~14 months. (chiranth2023asystematicreview pages 5-7, chiranth2023asystematicreview pages 4-5) - Axitinib: hearing response 25%; radiographic response 17% (small studies; toxicity frequent). (chiranth2023asystematicreview pages 4-5)

12.5 Experimental / translational directions (2023–2024)

Hippo/TEAD inhibition as a candidate strategy: TEAD palmitoylation inhibitors and YAP/TAZ genetic ablation regressed NF2-null schwannoma growth in preclinical models (positioned as a route toward future clinical translation). (laraba2023inhibitionofyaptazdriven pages 1-2)
AI-based tools for segmentation and monitoring may support clinical workflow and decision-making, but require standardization and reproducibility. (alsaleh2024theimpactof pages 1-3)

12.6 MAXO term suggestions (treatment normalization)

Suggested MAXO mappings (confirm in MAXO browser): - Microsurgical resection of tumor - Stereotactic radiosurgery - Fractionated stereotactic radiotherapy - Proton beam therapy - Anti-VEGF monoclonal antibody therapy (bevacizumab) - mTOR inhibitor therapy (everolimus) - Cochlear implantation (as rehabilitative hearing restoration; referenced as improving QoL outcomes in VS management literature, though quantitative CI outcomes were not extractable in the excerpts here) ( not citeable)

13. Prevention

13.1 Primary prevention

No primary prevention measures (e.g., vaccination, exposure modification) are established for sporadic VS in the retrieved evidence.

13.2 Secondary prevention / early detection

For NF2-associated disease, proactive MRI screening is recommended/used in registry contexts (mentioned in systematic review). (screnci2024bevacizumabforvestibular pages 1-2)

13.3 Genetic counseling

NF2-related schwannomatosis is autosomal dominant with mosaicism common in de novo cases, supporting family counseling and tailored genetic testing strategies (details beyond this were not extractable from retrieved excerpts). (kim2024nf2relatedschwannomatosis(nf2) pages 1-2)

14. Other Species / Natural Disease

Not available from the retrieved evidence.

15. Model Organisms

A 2023 primary study used mouse models (Periostin-Cre NF2fl/fl) and human primary schwannoma cells to test Hippo/TEAD targeting. (laraba2023inhibitionofyaptazdriven pages 1-2)
A 2024 review describes multiple preclinical candidate therapies tested in mouse/xenograft contexts for NF2-related schwannomas. (kim2024nf2relatedschwannomatosis(nf2) pages 6-7)

Structured summary artifact

The following table consolidates key identifiers, symptom frequencies, molecular mechanisms, diagnostics, treatments, outcomes statistics, and trial IDs from the retrieved evidence.

Domain	Key facts	Evidence
Disease / synonyms	Acoustic neuroma is the historical/common name for vestibular schwannoma (VS), a benign Schwann-cell tumor arising on the vestibulocochlear nerve (CN VIII); NF2-associated tumors are often bilateral.	(huo2024treatmentoptionsfor pages 1-2, screnci2024bevacizumabforvestibular pages 1-2, kim2024nf2relatedschwannomatosis(nf2) pages 1-2)
Epidemiology	VS is reported as the most common cerebellopontine angle tumor and about 8% of intracranial tumors; one 2024 meta-analysis background states annual incidence 10.4/100,000. Another 2024 review notes VS prevalence 3–5.2 per 100,000 person-years and that up to 95% are unilateral/sporadic.	(huo2024treatmentoptionsfor pages 1-2, king2024vestibularschwannomaand pages 1-2)
NF2-related epidemiology	NF2-related schwannomatosis prevalence estimated 1:50,000 and birth incidence 1:28,000; another review cites birth incidence 1 in 25,000–33,000. NF2 accounts for about ~7% of VS cases. About half of NF2 cases are inherited; among de novo cases 25–50% show somatic mosaicism.	(screnci2024bevacizumabforvestibular pages 1-2, kim2024nf2relatedschwannomatosis(nf2) pages 1-2)
Core phenotypes / frequencies	Recent cohort data: hearing loss 63.6% (or 71.5% in another cohort summary), disequilibrium 50%, headache 39.7%, tinnitus 25%, facial palsy 25%, trigeminal deficits 20.4%. Another meta-analysis background states >60% of patients have progressive hearing loss and tinnitus.	(aman2024currenttrendsin pages 5-6, aman2024currenttrendsin pages 1-2, huo2024treatmentoptionsfor pages 1-2)
Symptom domains / HPO suggestions	Suggested HPO mappings: hearing loss HP:0000365, tinnitus HP:0000360, vertigo/disequilibrium HP:0002321 / HP:0002329, headache HP:0002315, facial weakness/palsy HP:0000490, facial numbness/sensory disturbance HP:0003407.	(aman2024currenttrendsin pages 1-2, king2024vestibularschwannomaand pages 13-14, king2024vestibularschwannomaand pages 4-5)
Quality-of-life related findings	Tinnitus is emphasized as highly distressing and QoL-limiting. In one 2024 tinnitus review, 63% did not require tinnitus treatment while 36.6% had at least one episode of tinnitus distress; mean THI fell from 15.8 pre-op to 10.1 post-op at mean follow-up ~34.7 months.	(king2024vestibularschwannomaand pages 1-2, king2024vestibularschwannomaand pages 4-5)
Primary causal gene	NF2 on chromosome 22q12.2 encodes merlin, a FERM-domain membrane–cytoskeleton scaffolding tumor suppressor highly expressed in Schwann cells/adherens junctions. Loss of merlin alters cell adhesion, increases migration, reduces apoptosis, and promotes tumorigenesis.	(kim2024nf2relatedschwannomatosis(nf2) pages 1-2)
Key molecular pathways	Recurrently implicated pathways: Hippo/YAP/TAZ, VEGF/VEGFR2 angiogenic signaling, PI3K–AKT–mTOR, MEK–ERK, PAK, and TGFβ dysregulation. Merlin loss dysregulates Hippo signaling; VEGF-VEGFR2 can activate PI3K-Akt and MEK-ERK, suppressing Hippo kinases and promoting YAP/TAZ activity.	(laraba2023inhibitionofyaptazdriven pages 1-2, benton2024identifyingnewtargets pages 16-20, jones2024deconvolvingtheimmunea pages 35-39, benton2024identifyingnewtargets pages 98-101)
Mechanistic 2023–2024 advances	2023 primary data showed YAP/TAZ-driven TEAD activity is functionally required in NF2-null schwannoma; genetic ablation or TEAD palmitoylation inhibitors blocked/regressed tumor growth in vitro and in mouse models. Preclinical candidates in 2024 review include TEW7197, MLN4924 + GDC-0980, brigatinib, CUDC907, FASN inhibitors, and agents targeting merlin-related neo-PPIs.	(laraba2023inhibitionofyaptazdriven pages 1-2, kim2024nf2relatedschwannomatosis(nf2) pages 6-7)
Diagnostics: imaging	MRI and CT are preferred imaging modalities; gadolinium-enhanced MRI improves visualization. Typical MRI appearance described as an oval/round mass with T1 iso-/hypointense signal and heterogeneous hyperintense T2 signal. MRI is the key detection and treatment-assessment tool in NF2-related disease.	(alsaleh2024theimpactof pages 1-3, kim2024nf2relatedschwannomatosis(nf2) pages 1-2)
Diagnostics: audiology / functional testing	Hearing assessment commonly uses pure-tone audiometry (PTA) and word recognition score (WRS); one NF2 bevacizumab study defined hearing improvement/worsening as ≥10% WRS change (or ≥10 dB PTA if WRS = 100% at both times). BAEP/brainstem auditory evoked potentials are used intraoperatively; a 2024 study of 127 patients reported standardized BAEP V-wave latency/amplitude metrics improved prediction of hearing preservation.	(douwes2024bevacizumabtreatmentfor pages 2-4, chiranth2023asystematicreview pages 2-4, nghiemphu2024imagingasan pages 1-2)
Differential / anatomy-related manifestations	Large tumors may cause brainstem compression, hydrocephalus, facial paresis/paresthesia, vertigo, and headache; VS is anatomically related to the trigeminal, facial, and cochlear nerves, explaining cranial neuropathies.	(huo2024treatmentoptionsfor pages 1-2)
Observation / conservative management	Observation remains a standard option, especially for selected patients; in the 2024 network meta-analysis, microsurgery and radiosurgery had better local tumor control than observation, while observation ranked relatively well for trigeminal nerve protection compared with microsurgery.	(huo2024treatmentoptionsfor pages 1-2)
Microsurgery outcomes	2024 long-term hearing meta-analysis reported pooled 10-year serviceable hearing preservation 74.5% (95% CI 63.5–84.1%) for microsurgery in hearing-preservation cohorts. Another 2024 review states hearing preservation after surgery is <25% overall in broader literature. Surgical mortality was reported 0.38% and overall complication rate 5.3% in one review.	(daloiso2024long‐termhearingoutcome pages 1-2, pontillo2024hearingpreservationsurgery pages 1-2, king2024vestibularschwannomaand pages 1-2)
SRS / FSRT / ConFSRT comparative outcomes	2024 network meta-analysis found MS and radiosurgery had better local control than observation. For preserved hearing, ranking was FSRT 5 fractions > FSRT 3 fractions > SRS > ConFSRT > Observation > MS. For facial nerve protection, ranking was SRS > ConFSRT > Observation > FSRT 3 fractions > FSRT 5 fractions > MS. For disequilibrium/vertigo improvement, SRS ranked best.	(huo2024treatmentoptionsfor pages 1-2)
SRS long-term hearing	In the 2024 long-term meta-analysis (≥5-year audiologic follow-up), pooled maintenance of serviceable hearing after SRS at 10 years was 18.1% (95% CI 1.7–43.3%), with wide variability.	(daloiso2024long‐termhearingoutcome pages 1-2)
CyberKnife outcomes	2024 systematic review of 13 studies / 493 participants found pooled hearing preservation 68% (95% CI 59–76%) after CyberKnife at mean follow-up 42.96 months; longer follow-up was associated with lower preservation rates.	(tavares2024hearingfunctionafter pages 1-2)
Proton beam outcomes	2023 systematic review/meta-analysis of 8 studies / 587 patients: tumor control 95.4%, progression 4.6%, trigeminal nerve preservation 95.6%, facial nerve preservation 93.7%, hearing preservation 40.6%, hydrocephalus requiring shunt 1.4%. Authors concluded proton therapy does not offer clear hearing/facial nerve advantage over most current SRS series.	(santacroce2023protonbeamradiation pages 1-2)
Bevacizumab (systematic review)	2024 systematic review in NF2-associated VS (9 studies, 176 patients): partial tumor volume reduction ≥20% in 40%, stabilization 50%, progression 10%; hearing improvement 36%, stabilization 46%, deterioration 18%; severe adverse events 13%; 18% had no side effects; regrowth after discontinuation can occur.	(screnci2024bevacizumabforvestibular pages 1-2)
Bevacizumab (single-center 2024)	Single-center 2024 series (17 patients, 7.5 mg/kg, median/mean treatment about 7.1 months): hearing improvement 40%, stable hearing 53%, hearing loss 7%; tumor regression 31%, stable 69%; symptomatic improvement 41%; treatment discontinuation for adverse events 29%; hypertension 82%, fatigue 29%.	(douwes2024bevacizumabtreatmentfor pages 13-14)
Everolimus	2024 phase II report in 12 NF2 patients (NCT01345136): after 52 weeks, median annual VS growth rate decreased from 77.2% to 29.4%; no radiographic responses (≥20% decrease), 3/8 (37.5%) had stable disease, 7/8 had stable hearing; early volumetric MRI at 3 months predicted stabilization at 12 months.	(nghiemphu2024imagingasan pages 1-2, NCT01345136 chunk 1)
Other targeted therapies	2023 systematic review: lapatinib phase II yielded hearing response 31% (4/13) and radiographic response 6% (1/17), median TTP ~14 months; axitinib showed hearing response 25% and radiographic response 17%; everolimus and erlotinib showed minimal/no hearing or radiographic responses in small cohorts.	(chiranth2023asystematicreview pages 5-7, chiranth2023asystematicreview pages 4-5, chiranth2023asystematicreview pages 2-4)
Clinical trials / IDs	Relevant trial IDs identified in gathered evidence: NCT01345136 (everolimus/RAD001 phase II), NCT01207687 (bevacizumab phase II), NCT02129647 (axitinib phase II), NCT04374305 (INTUITT-NF2 ongoing platform/phase II), NCT01767792 (bevacizumab in children/young adults), NCT00973739 (lapatinib), NCT00863122 (lapatinib concentration/activity), NCT01490476 and NCT01419639 (everolimus), NCT05685836 (89Zr-bevacizumab PET/CT imaging).	(nghiemphu2024imagingasan pages 1-2, NCT01345136 chunk 1)
Real-world implementation / AI	2024 systematic review of AI in acoustic neuroma reported successful models for volume estimation, segmentation, tumor differentiation, radiomics, QoL evaluation, monitoring, robotic-assisted surgery, and decision support, reflecting growing translational use of routine MRI datasets.	(alsaleh2024theimpactof pages 1-3)

Table: This table compiles high-yield disease facts for acoustic neuroma/vestibular schwannoma, including epidemiology, phenotypes, molecular mechanisms, diagnostics, treatment outcomes, and relevant trial identifiers. It is designed as a rapid reference for knowledge-base population using only gathered evidence.

URLs and publication dates (from retrieved sources)

Huo et al., BMC Cancer, Dec 2024. https://doi.org/10.1186/s12885-024-13242-1 (huo2024treatmentoptionsfor pages 1-2)
Screnci et al., Journal of Clinical Medicine, Dec 2024. https://doi.org/10.3390/jcm13237488 (screnci2024bevacizumabforvestibular pages 1-2)
Kim et al., International Journal of Molecular Sciences, Jun 2024. https://doi.org/10.3390/ijms25126558 (kim2024nf2relatedschwannomatosis(nf2) pages 1-2)
Nghiemphu et al., Journal of Neuro-Oncology, Feb 2024. https://doi.org/10.1007/s11060-024-04596-4 (nghiemphu2024imagingasan pages 1-2)
Douwes et al., Cancers, Apr 2024. https://doi.org/10.3390/cancers16081479 (douwes2024bevacizumabtreatmentfor pages 13-14)
Tavares & Bahmad, Int Arch Otorhinolaryngol, Jul 2024. https://doi.org/10.1055/s-0044-1787736 (tavares2024hearingfunctionafter pages 1-2)
Santacroce et al., Neurosurgical Review, Jul 2023. https://doi.org/10.1007/s10143-023-02060-x (santacroce2023protonbeamradiation pages 1-2)
Laraba et al., Brain, Sep 2023. https://doi.org/10.1093/brain/awac342 (laraba2023inhibitionofyaptazdriven pages 1-2)
Alsaleh, Technology and Health Care, Nov 2024. https://doi.org/10.3233/thc-232043 (alsaleh2024theimpactof pages 1-3)
Aman et al., Romanian Journal of Neurology, Sep 2024. https://doi.org/10.37897/rjn.2024.3.7 (aman2024currenttrendsin pages 1-2)
ClinicalTrials.gov NCT01345136, posted record (year in record excerpt: 2015). https://clinicaltrials.gov/study/NCT01345136 (NCT01345136 chunk 1)

References

(screnci2024bevacizumabforvestibular pages 1-2): Melina Screnci, Mathilde Puechmaille, Quentin Berton, Toufic Khalil, Thierry Mom, and Guillaume Coll. Bevacizumab for vestibular schwannomas in neurofibromatosis type 2: a systematic review of tumor control and hearing preservation. Journal of Clinical Medicine, 13:7488, Dec 2024. URL: https://doi.org/10.3390/jcm13237488, doi:10.3390/jcm13237488. This article has 5 citations.
(huo2024treatmentoptionsfor pages 1-2): Xianhao Huo, Xu Zhao, Xiaozhuo Liu, Yifan Zhang, Jihui Tian, and Mei Li. Treatment options for unilateral vestibular schwannoma: a network meta-analysis. BMC Cancer, Dec 2024. URL: https://doi.org/10.1186/s12885-024-13242-1, doi:10.1186/s12885-024-13242-1. This article has 6 citations and is from a peer-reviewed journal.
(santacroce2023protonbeamradiation pages 1-2): Antonio Santacroce, Mioara- Florentina Trandafirescu, Marc Levivier, David Peters, Christoph Fürweger, Iuliana Toma-Dasu, Mercy George, Roy Thomas Daniel, Raphael Maire, Makoto Nakamura, Mohamed Faouzi, Luis Schiappacasse, Alexandru Dasu, and Constantin Tuleasca. Proton beam radiation therapy for vestibular schwannomas-tumor control and hearing preservation rates: a systematic review and meta-analysis. Neurosurgical Review, Jul 2023. URL: https://doi.org/10.1007/s10143-023-02060-x, doi:10.1007/s10143-023-02060-x. This article has 7 citations and is from a peer-reviewed journal.
(kim2024nf2relatedschwannomatosis(nf2) pages 1-2): Bae-Hoon Kim, Yeon-Ho Chung, Tae-Gyun Woo, So-mi Kang, Soyoung Park, Minju Kim, and Bum-Joon Park. Nf2-related schwannomatosis (nf2): molecular insights and therapeutic avenues. International Journal of Molecular Sciences, 25:6558, Jun 2024. URL: https://doi.org/10.3390/ijms25126558, doi:10.3390/ijms25126558. This article has 11 citations.
(aman2024currenttrendsin pages 5-6): Renindra Ananda Aman, Nadya Zaragita, Fitrie Desbassarie, Bima Andyan Wicaksana, and Nicholas Calvin. Current trends in vestibular schwannoma management at a referral center in indonesia: a cross-sectional study with retrospective data collection. Romanian Journal of Neurology, 23:272-280, Sep 2024. URL: https://doi.org/10.37897/rjn.2024.3.7, doi:10.37897/rjn.2024.3.7. This article has 0 citations.
(aman2024currenttrendsin pages 1-2): Renindra Ananda Aman, Nadya Zaragita, Fitrie Desbassarie, Bima Andyan Wicaksana, and Nicholas Calvin. Current trends in vestibular schwannoma management at a referral center in indonesia: a cross-sectional study with retrospective data collection. Romanian Journal of Neurology, 23:272-280, Sep 2024. URL: https://doi.org/10.37897/rjn.2024.3.7, doi:10.37897/rjn.2024.3.7. This article has 0 citations.
(laraba2023inhibitionofyaptazdriven pages 1-2): Liyam Laraba, Lily Hillson, Julio Grimm de Guibert, Amy Hewitt, Maisie R Jaques, Tracy T Tang, Leonard Post, Emanuela Ercolano, Ganesha Rai, Shyh-Ming Yang, Daniel J Jagger, Waldemar Woznica, Philip Edwards, Aditya G Shivane, C Oliver Hanemann, and David B Parkinson. Inhibition of yap/taz-driven tead activity prevents growth of nf2-null schwannoma and meningioma. Brain, 146:1697-1713, Sep 2023. URL: https://doi.org/10.1093/brain/awac342, doi:10.1093/brain/awac342. This article has 62 citations and is from a highest quality peer-reviewed journal.
(king2024vestibularschwannomaand pages 1-2): Ava M. King, Jaimee N. Cooper, Karina Oganezova, Jeenu Mittal, Keelin McKenna, Dimitri A. Godur, Max Zalta, Ali A. Danesh, Rahul Mittal, and Adrien A. Eshraghi. Vestibular schwannoma and tinnitus: a systematic review of microsurgery compared to gamma knife radiosurgery. Journal of Clinical Medicine, 13:3065, May 2024. URL: https://doi.org/10.3390/jcm13113065, doi:10.3390/jcm13113065. This article has 6 citations.
(king2024vestibularschwannomaand pages 4-5): Ava M. King, Jaimee N. Cooper, Karina Oganezova, Jeenu Mittal, Keelin McKenna, Dimitri A. Godur, Max Zalta, Ali A. Danesh, Rahul Mittal, and Adrien A. Eshraghi. Vestibular schwannoma and tinnitus: a systematic review of microsurgery compared to gamma knife radiosurgery. Journal of Clinical Medicine, 13:3065, May 2024. URL: https://doi.org/10.3390/jcm13113065, doi:10.3390/jcm13113065. This article has 6 citations.
(jones2024deconvolvingtheimmunea pages 35-39): AP Jones. Deconvolving the immune microenvironment of vestibular schwannoma and the implications for t-cell immunotherapy in nf2-related schwannomatosis. Unknown journal, 2024.
(nghiemphu2024imagingasan pages 1-2): Phioanh Leia Nghiemphu, Jeremie Vitte, Eva Dombi, Thien Nguyen, Naveed Wagle, Akira Ishiyama, Ali R. Sepahdari, David Cachia, Brigitte C. Widemann, Derald E. Brackmann, Joni K. Doherty, Michel Kalamarides, and Marco Giovannini. Imaging as an early biomarker to predict sensitivity to everolimus for progressive nf2-related vestibular schwannoma. Journal of Neuro-Oncology, 167:339-348, Feb 2024. URL: https://doi.org/10.1007/s11060-024-04596-4, doi:10.1007/s11060-024-04596-4. This article has 7 citations and is from a peer-reviewed journal.
(kim2024nf2relatedschwannomatosis(nf2) pages 6-7): Bae-Hoon Kim, Yeon-Ho Chung, Tae-Gyun Woo, So-mi Kang, Soyoung Park, Minju Kim, and Bum-Joon Park. Nf2-related schwannomatosis (nf2): molecular insights and therapeutic avenues. International Journal of Molecular Sciences, 25:6558, Jun 2024. URL: https://doi.org/10.3390/ijms25126558, doi:10.3390/ijms25126558. This article has 11 citations.
(alsaleh2024theimpactof pages 1-3): Hadeel Alsaleh. The impact of artificial intelligence in the diagnosis and management of acoustic neuroma: a systematic review. Technology and Health Care, 32:3801-3813, Nov 2024. URL: https://doi.org/10.3233/thc-232043, doi:10.3233/thc-232043. This article has 5 citations and is from a peer-reviewed journal.
(douwes2024bevacizumabtreatmentfor pages 2-4): Jules P. J. Douwes, Erik F. Hensen, Jeroen C. Jansen, Hans Gelderblom, and Josefine E. Schopman. Bevacizumab treatment for patients with nf2-related schwannomatosis: a single center experience. Cancers, 16:1479, Apr 2024. URL: https://doi.org/10.3390/cancers16081479, doi:10.3390/cancers16081479. This article has 13 citations.
(daloiso2024long‐termhearingoutcome pages 1-2): Antonio Daloiso, Diego Cazzador, Stefano Concheri, Giulia Tealdo, and Elisabetta Zanoletti. Long‐term hearing outcome for vestibular schwannomas after microsurgery and radiotherapy: a systematic review and meta‐analysis. Otolaryngology–Head and Neck Surgery, 171:1670-1681, Jul 2024. URL: https://doi.org/10.1002/ohn.910, doi:10.1002/ohn.910. This article has 8 citations.
(tavares2024hearingfunctionafter pages 1-2): Matheus Pedrosa Tavares and Fayez Bahmad Jr. Hearing function after cyberknife for vestibular schwannoma: a systematic review. International Archives of Otorhinolaryngology, 28:e543-e551, Jul 2024. URL: https://doi.org/10.1055/s-0044-1787736, doi:10.1055/s-0044-1787736. This article has 2 citations.
(pontillo2024hearingpreservationsurgery pages 1-2): Vito Pontillo, Valentina Foscolo, Francesco Salonna, Francesco Barbara, Maria Teresa Bozzi, Raffaella Messina, Francesco Signorelli, and Nicola Antonio Adolfo Quaranta. Hearing preservation surgery for vestibular schwannoma: a systematic review and meta-analysis. Acta Otorhinolaryngologica Italica, 44:S86-S93, May 2024. URL: https://doi.org/10.14639/0392-100x-suppl.1-44-2024-n2900, doi:10.14639/0392-100x-suppl.1-44-2024-n2900. This article has 8 citations and is from a peer-reviewed journal.
(douwes2024bevacizumabtreatmentfor pages 13-14): Jules P. J. Douwes, Erik F. Hensen, Jeroen C. Jansen, Hans Gelderblom, and Josefine E. Schopman. Bevacizumab treatment for patients with nf2-related schwannomatosis: a single center experience. Cancers, 16:1479, Apr 2024. URL: https://doi.org/10.3390/cancers16081479, doi:10.3390/cancers16081479. This article has 13 citations.
(NCT01345136 chunk 1): Study of RAD001 for Treatment of NF2-related Vestibular Schwannoma. Jonsson Comprehensive Cancer Center. 2015. ClinicalTrials.gov Identifier: NCT01345136
(chiranth2023asystematicreview pages 5-7): Shivani Chiranth, Seppo W Langer, Hans Skovgaard Poulsen, and Thomas Urup. A systematic review of targeted therapy for vestibular schwannoma in patients with nf2-related schwannomatosis. Neuro-Oncology Advances, Aug 2023. URL: https://doi.org/10.1093/noajnl/vdad099, doi:10.1093/noajnl/vdad099. This article has 23 citations and is from a peer-reviewed journal.
(chiranth2023asystematicreview pages 4-5): Shivani Chiranth, Seppo W Langer, Hans Skovgaard Poulsen, and Thomas Urup. A systematic review of targeted therapy for vestibular schwannoma in patients with nf2-related schwannomatosis. Neuro-Oncology Advances, Aug 2023. URL: https://doi.org/10.1093/noajnl/vdad099, doi:10.1093/noajnl/vdad099. This article has 23 citations and is from a peer-reviewed journal.
(king2024vestibularschwannomaand pages 13-14): Ava M. King, Jaimee N. Cooper, Karina Oganezova, Jeenu Mittal, Keelin McKenna, Dimitri A. Godur, Max Zalta, Ali A. Danesh, Rahul Mittal, and Adrien A. Eshraghi. Vestibular schwannoma and tinnitus: a systematic review of microsurgery compared to gamma knife radiosurgery. Journal of Clinical Medicine, 13:3065, May 2024. URL: https://doi.org/10.3390/jcm13113065, doi:10.3390/jcm13113065. This article has 6 citations.
(benton2024identifyingnewtargets pages 16-20): Dorothy Benton. Identifying new targets and drug combinations in neurofibromatosis type 2. ArXiv, 2024. URL: https://doi.org/10.17918/00010718, doi:10.17918/00010718. This article has 1 citations.
(benton2024identifyingnewtargets pages 98-101): Dorothy Benton. Identifying new targets and drug combinations in neurofibromatosis type 2. ArXiv, 2024. URL: https://doi.org/10.17918/00010718, doi:10.17918/00010718. This article has 1 citations.
(chiranth2023asystematicreview pages 2-4): Shivani Chiranth, Seppo W Langer, Hans Skovgaard Poulsen, and Thomas Urup. A systematic review of targeted therapy for vestibular schwannoma in patients with nf2-related schwannomatosis. Neuro-Oncology Advances, Aug 2023. URL: https://doi.org/10.1093/noajnl/vdad099, doi:10.1093/noajnl/vdad099. This article has 23 citations and is from a peer-reviewed journal.

Ask OpenScientist

OpenScientist Report

Definitions

Subtypes

Pathophysiology

Pathograph

Phenotypes

Genetic Associations

Treatments

Experimental Models

Source YAML

References & Deep Research

Deep Research

1. Disease Information

1.1 Overview (current understanding)

1.2 Key identifiers

1.3 Evidence source type

2. Etiology

2.1 Disease causal factors

2.2 Risk factors

2.3 Protective factors

2.4 Gene–environment interaction

3. Phenotypes

3.1 Core clinical phenotypes (with characteristics and frequencies)

3.2 Quality of life impact

3.3 HPO term suggestions (phenotype normalization)

4. Genetic/Molecular Information

4.1 Causal genes

4.2 Molecular pathways and cellular processes (current understanding)

4.3 Epigenetics / multi-omics

4.4 GO and CL term suggestions (mechanism annotation)

5. Environmental Information

6. Mechanism / Pathophysiology

6.1 Causal chain (integrated model)

6.2 Upstream vs downstream

7. Anatomical Structures Affected

7.1 Organ/tissue level

7.2 UBERON suggestions

7.3 Lateralization

8. Temporal Development

8.1 Onset and progression

8.2 Staging / grading

9. Inheritance and Population

9.1 Epidemiology (VS)

9.2 NF2-related schwannomatosis (inheritance)

10. Diagnostics

10.1 Imaging

10.2 Audiology and electrophysiology

10.3 Emerging/real-world implementations (2023–2024)

10.4 Differential diagnosis

11. Outcome / Prognosis

11.1 Treatment-associated functional outcomes (hearing)

11.2 Morbidity/QoL

12. Treatment

12.1 Treatment strategy (current practice)

12.2 Radiotherapy/radiosurgery outcomes

12.3 Surgery outcomes

12.4 Pharmacotherapy / targeted therapy (NF2-related VS)

12.5 Experimental / translational directions (2023–2024)

12.6 MAXO term suggestions (treatment normalization)

13. Prevention

13.1 Primary prevention

13.2 Secondary prevention / early detection

13.3 Genetic counseling

14. Other Species / Natural Disease

15. Model Organisms

Structured summary artifact

URLs and publication dates (from retrieved sources)